Skip to main content

Table 3 ELABELA levels according to disease stage and tests in patients with CLL

From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

VariablesCLLELABELA (ng/ml)p
STAGEN = 42  
 07 (16.7)7.6 (6.2–19.6)0.361
 116 (38.1)6.3 (0.6–19.7)
 210 (23.8)6.3 (0.6–9.7)
 36 (14.3)6.4 (0.7–15.8)
 43 (7.1)4.8 (1.1–7.3)
DCN = 42  
 Negative34 (81.0)7 (0.6–19.7)0.134
 Positive5 (11.9)2.9 (0.7–6.9)
 Weak positive3 (7.1)3 (1.1–19.6) 
p53N = 21  
 Negative15 (71.4)7.6 (0.7–19.7)0.080
 Positive6 (28.6)3.4 (0.6–8.8)
DEL13qN = 14  
 Negative5 (35.7)6.2 (0.7–9.7)0.898
 Positive9 (64.3)6.6 (0.6–16.4)
  1. ELABELA level is presented as median (min-max). Categorical variables are presented as number (%)
  2. Abbreviations: CLL Chronic lymphocytic leukaemia